Table 42. Vitamin D and Blood Pressure: Characteristics of Rcts (Updated from Original Report)

Table 42. Vitamin D and Blood Pressure: Characteristics of Rcts (Updated from Original Report)

<p>Table 42. Vitamin D and blood pressure: Characteristics of RCTs (updated from original report)</p><p>Author Year Study Name Background Calcium Location Population Intake & Vitamin D Comparisons Compliance Comments (Latitude) Data [PMID]</p><p>SYSTOLIC BLOOD PRESSURE Radioreceptor assay 237 Scragg 1995 No HTN 25(OH)D: 34.5 nmol/L Vit D3 100,000 IU nd Complete trial Health Cambridge, UK  (treatment group), 32.25 (2.5 mg) one-time performed in winter (52°N) status nmol/L (control group) dose vs. Placebo 70 (63-76) [7498100] Mean age (range), y 46% Male (%) Radioimmunoassay 238 Pfeifer 2001 Healthy, low Vit D 25(OH)D < 50 nmol/L Vit D3 + Ca 95±12% for the Ca Health Lower Saxony, Germany  supplement vs. Ca tablets and 96±10% for status (52°N) supplement the Vit D3 + Ca tablets 75 (70-86) [11297596] Mean age (pill counting) (range), y 0 Male (%)</p><p>Healthy, obese 25(OH)D: 36.5 nmol/L Vit D3 120,000 IU 100% (implied); Excluded subjects who Health  (treatment group), 30.0 every 2 weeks vs. supervised home visits refused subsequent Nagpal 200996 status nmol/L (control group) Placebo blood draws New Delhi, India 44 (8) (28.5°N) Mean age [19125756] (SD), y 100% Male (%) DIASTOLIC BLOOD PRESSURE Radioreceptor assay 237 Scragg 1995 No HTN 25(OH)D: 34.5 nmol/L Vit D3 100,000 IU nd Complete trial Health Cambridge, UK  (treatment group), 32.25 (2.5 mg) one-time performed in winter (52°N) status nmol/L (control group) dose vs. Placebo 70 (63-76) [7498100] Mean age (range), y 46% Male (%) Radioimmunoassay Pfeifer 2001238 Healthy, low Vit D 25(OH)D < 50 nmol/L 95±12% for the Ca Health Lower Saxony, Germany  tablets and 96±10% for status</p><p>H-1 Author Year Study Name Background Calcium Location Population Intake & Vitamin D Comparisons Compliance Comments (Latitude) Data [PMID]</p><p>75 (70-86) (52°N) Mean age Vit D3 + Ca the Vit D3 + Ca tablets [11297596] supplement vs. Ca (pill counting) (range), y supplement 0 Male (%) 96 Nagpal 2009 Healthy, obese 25(OH)D: 36.5 nmol/L Vit D3 120,000 IU 100% (implied); Excluded subjects who Health New Delhi, India  (treatment group), 30.0 every 2 weeks vs. supervised home visits refused subsequent (28.5°N) status nmol/L (control group) Placebo blood draws 44 (8) [19125756] Mean age (SD), y 100% Male (%) NEW Studies Radioimmunoassay 227 Forman 2013 Healthy Serum vitamin D- 39.3 Vit D3 100,000 96.6% Health Boston, MA  (26.8-83.5 IQR) nmol/L IU/day status Vs. 51 (44-59) Mean age (range), y 34.6% Vit D₃ 2000 IU/day Male (%)</p><p>Vs.</p><p>Vit D₃ 4000 IU/day</p><p>Vs. placebo Jorde 2010230 Using blood pressure or 58.0 ± 21.1 nmol/L Vitamin D⁄ placebo Health Norway  lipid lowering medication capsules 95%-DD status Overweight/Obese group, 96%-DP group 47.5 (SD 11.4) and 96%-PP group Mean age (SD), y</p><p>H-2 Author Year Study Name Background Calcium Location Population Intake & Vitamin D Comparisons Compliance Comments (Latitude) Data [PMID]</p><p>35.8% Male (%)</p><p>DD (40,000 IU Vit calcium tablets 82%, 84% and 83%, respectively. D₃/week)+500 mg </p><p> calcium/day Vs. DP (20,000 IU Vit Enzyme-linked Immunoabsorption Assay Salehpour 2012234 Overweight, obese Serum 25(OH)D Vit D 25 μg/day nd Health D₃/week)+500 mg Tehran, Iran  Vs. status Vit D group: 36.8 +/- 30 placebo 38 (SD 8.1) Mean age nmol/l calcium/day (SD), y Vs. 0% Placebo group - 46.9 +/- PP (placebo)+500 Male (%) 32 nmol/l mg calcium/day Witham 2013235 Healthy <50 nmol/L Vit d3 100,000 units nd H UK  Vs. ealth status 39.4 (SD 11.8) placebo  M ean age 0% (SD), y  M ale (%)</p><p>H-3 Author Year Study Name Background Calcium Location Population Intake & Vitamin D Comparisons Compliance Comments (Latitude) Data [PMID]</p><p>Toxqui 2013228 Healthy Serum: D-placebo 62.9 ± vit d 200 IU/day >96% H Spain  20.8 nmol/L Vs. ealth status 26.5 (SD 3.8) D-fortified 62.3 ± 20.8 placebo  M nmol/L ean age 0% (SD), y  M ale (%) HPLC-tandem mass spectrometry Gepner 2012229 Healthy Serum vitamin D- 78.3+/- Placebo nd Health Madison, WI  Postmenopausal 26.5 nmol/L Vs. status Mean age  63.9 (SD 3) (range), y Vit D₃ 2500 IU/day 0% Male (%) Wood 2012231 Healthy Serum 25(OH)D 400 IU Vit D/day nd Health Aberdeen, UK  Post-menopausal placebo: 36.18 ± 17.1 Vs. status nmol/l placebo 63.9 (SD 2.3) Mean age 400 IU D3 group: 32.74 (range), y ± 12.9 nmol/l 0% 1000 IU D3 group: 32.41 Male (%) ± 13.8 nmol/l Wamberg 2013236 Overweight/obese 34.6±10.3 nmol/L 7000 IU 94±8% H  cholecalciferol ealth status 41.2 (18-50) vs.  M (SD 6.8) placebo ean age (SD), y 27%  M ale (%) Not reported Zhu 2013232 Healthy Habitual Ca intake (energy-restricted 95.8% in the calcium+D Health Shanghai, China  diet+600 mg group status CaD group - 426.5 +/- calcium+125 IU Vit 20.3 (SD 0.8) Mean age 152.2 mg/d D)/day (range), y Vs. 14.3% Control group - 392.1 +/- energy-restricted Male (%) 141.1 mg/d diet alone (control)</p><p>H-4 Author Year Study Name Background Calcium Location Population Intake & Vitamin D Comparisons Compliance Comments (Latitude) Data [PMID]</p><p>Daly 2009233 Healthy, obese Serum 25(OH)D (400 ml reduced fact 85 ± 21% Health Melbourne, Australia  milk group: 78 ± 23 milk fortified with status nmol/l 1000 mg 61.2 (SD 7.5) Mean age control group: 76 ± 23 calcium+800 IU Vit (SD), y nmol/l D)/day 100% Vs. Male (%) control (no additional fortified milk) (400 ml reduced fact milk fortified with 1000 mg clacium+800 IU Vit D)/day Vs. control (no additional fortified milk)</p><p>H-5</p>

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    5 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us